000834113 001__ 834113
000834113 005__ 20210129230542.0
000834113 0247_ $$2doi$$a10.18632/oncotarget.15437
000834113 0247_ $$2WOS$$aWOS:000396877500053
000834113 037__ $$aFZJ-2017-04114
000834113 041__ $$aEnglish
000834113 082__ $$a610
000834113 1001_ $$0P:(DE-HGF)0$$aMorgenroth, Agnieszka$$b0$$eCorresponding author
000834113 245__ $$aRadioiodinated indomethacin amide for molecular imaging of cyclooxygenase-2 expressing tumorsinm-5
000834113 260__ $$a[S.l.]$$bImpact Journals LLC$$c2017
000834113 3367_ $$2DRIVER$$aarticle
000834113 3367_ $$2DataCite$$aOutput Types/Journal article
000834113 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1501140895_26322
000834113 3367_ $$2BibTeX$$aARTICLE
000834113 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000834113 3367_ $$00$$2EndNote$$aJournal Article
000834113 520__ $$aCyclooxygenase-2 (COX-2) is an important biomarker in several tumors. Available imaging probes display relatively low tumor to background ratios (smaller than 2:1). We evaluated newly developed indomethacin (Ind) derivatives for in vivo molecular imaging of COX-2 expressing carcinoma. Radioiodinated Ind derivatives Ind-NH-(CH2)4-NH-3-[I-125]I-Bz ([I-125]5), Ind-NH-(CH2)4-NH-5-[I-124/125]I-Nic ([I-124/125]6) and Ind-NH-(CH2)4-NH-5-[I-125]I-Iphth ([I-125]7) were prepared from the respective SnBu3-precursors (45–80% radiochemical yield; > 95% radiochemical purity). The cellular uptake of [I-125]5 and [I-125]6 correlated with COX-2 expression determined by SDS page/Western blot analysis. [I-125]5 was predominantly localized in the cell membrane while [I-125]6 was internalized and displayed a diffuse and favorable cytoplasmic distribution. In contrast, [I-125]7 showed only low uptake in COX-2 positive cells. Co-incubation with the COX-2 inhibitor Celecoxib led to an almost complete suppression of cellular uptake of [I-125]5 and [I-125]6. In vivo molecular imaging using positron emission tomography (PET) in SCID mice xenografted with COX-2+ (HT29) and COX-2− (HCT116) human colorectal carcinoma cells was performed for [I-124]6. HT29 xenografts displayed a significantly higher uptake than HCT-116 xenografts (5.6 ± 1.5 vs. 0.5 ± 0.1 kBq/g, P < 0.05) with an extraordinary high tumor to muscle ratio (50.3 ± 1.5). Immunohistological staining correlated with the imaging data. In conclusion, the novel radioiodinated indomethacin derivative ([I-124/125]6) could become a valuable tool for development of molecular imaging probes for visualization of COX-2 expressing tumors.
000834113 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000834113 588__ $$aDataset connected to CrossRef
000834113 7001_ $$0P:(DE-HGF)0$$aVogg, Andreas T. J.$$b1
000834113 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b2$$ufzj
000834113 7001_ $$0P:(DE-Juel1)132318$$aMottaghy, Felix M.$$b3$$ufzj
000834113 7001_ $$0P:(DE-HGF)0$$aZlatopolskiy, Boris D.$$b4
000834113 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.15437$$n11$$p18059-18069$$tOncoTarget$$v8$$x1949-2553$$y2017
000834113 8564_ $$uhttps://juser.fz-juelich.de/record/834113/files/15437-227981-3-PB.pdf$$yRestricted
000834113 909CO $$ooai:juser.fz-juelich.de:834113$$pVDB
000834113 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b2$$kFZJ
000834113 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132318$$aForschungszentrum Jülich$$b3$$kFZJ
000834113 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000834113 9141_ $$y2017
000834113 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOTARGET : 2015
000834113 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000834113 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000834113 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000834113 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000834113 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000834113 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000834113 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000834113 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOTARGET : 2015
000834113 920__ $$lyes
000834113 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000834113 980__ $$ajournal
000834113 980__ $$aVDB
000834113 980__ $$aI:(DE-Juel1)INM-5-20090406
000834113 980__ $$aUNRESTRICTED